FDA’s Trade Name Pilot Should Include Third-Party Reviews, Industry Says
Foreseeing battles over FDA and industry trade name discrepancies in a proposed pilot program, industry representatives are recommending that an independent, third-party review take place
You may also be interested in...
The success of FDA's pilot program for review of trade names will likely depend on the extent to which companies feel that taking on the burden will produce specific benefits for them
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.